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Background: The Birt-Hogg-Dubé syndrome is a rare cancer susceptibility syndrome characterised by renal
tumours, lung cysts and pneumothoraces, and fibrofolliculomas. It is caused by dominantly inherited mutations in
FLCN. Our objective was to report renal tumour characteristics in a large series of patients with the Birt-Hogg-Dubé
syndrome.
Methods: We studied French Birt-Hogg-Dubé patients with a history of renal tumour.
Results: We included 33 patients with 21 distinct germline FLCN mutations. Median age at diagnosis of first renal
tumour was 46, and age varied from 20 to 83. Twenty cases had one renal tumour, the remainder had two or more
tumours. Most cases (23/33, 70%) had oncocytoma or renal cell carcinoma of the chromophobe or hybrid
chromophobe-oncocytoma type, three had clear cell carcinoma (9%), and the other seven had carcinoma of
papillary, undifferentiated or undetermined histology. Four cases had metastatic disease, although none died of it.
Conclusions: Age at renal tumour diagnosis was highly variable, highlighting the need for regular surveillance from
young adulthood to old age. Most cases had tumour types classically associated with Birt-Hogg-Dubé, i.e. oncocytoma
or renal cell carcinoma of the chromophobe or hybrid type. Nevertheless, 9% had clear cell renal cell carcinoma.
Geneticists, urologists and oncologists should therefore be alert to the possibility of Birt-Hogg-Dubé in patients
with renal cell carcinoma of clear cell histology, especially if there are associated manifestations. Finally, the
behaviour of metastatic carcinoma seemed more indolent than in sporadic renal cancers.
Keywords: Renal cell carcinoma, Neoplastic syndromes, Hereditary, Birt-Hogg-Dubé, Genetic predisposition to
disease, FolliculinIntroduction
The Birt-Hogg-Dubé syndrome (BHD) is a rare cancer
susceptibility syndrome characterised mainly by renal
cell tumours, lung cysts and pneumothoraces, and skin
papules named fibrofolliculomas [1]. It is caused by
germline mutations in the FLCN gene, which are inherited* Correspondence: pbenusiglio.wk@gmail.com
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article, unless otherwise stated.in a dominant fashion [1]. FLCN codes for folliculin, a
protein that operates in the mTOR pathway and leads,
when inactivated, to increased mitochondrial oxidative
metabolism [2,3]. Phenotype is variable among patients
with BHD. Indeed, renal cell tumours affects up to 34% of
mutation carriers, and consists predominantly of chromo-
phobe renal cell carcinomas (RCC), benign oncocytomas,
and RCC with hybrid chromophobe – oncocytoma hist-
ology [4-7]. Twenty-four to 37% of BHD cases present with
at least one episode of pneumothorax in their lifetime, and
79% to 84% have skin fibrofolliculomas [4,5,8].tral Ltd. This is an Open Access article distributed under the terms of the
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33 BHD patients, among them four cases with metastatic,
albeit indolent disease.
Patients and methods
In France, patients are referred to accredited cancer
genetics clinics throughout the country when genetic
susceptibility to renal cell tumours is suspected. Not all
patients present with a personal or family history of renal
cell tumour. Indeed, some have non-renal manifestations
suggestive of a syndrome in which renal cell tumour risk
is increased, and others are healthy relatives of individuals
with an established genetic predisposition. The genes most
commonly analysed in hereditary RCC are VHL (associ-
ated with von Hippel-Lindau disease), FH (Hereditary
Leiomyomatosis with RCC), FLCN (BHD), SDHB (PGL4
syndrome), andMET (Hereditary Papillary RCC) [9].
On November 15, 2013, we explored two overlapping
sources, the PREDIR National Hereditary Kidney Cancer
Centre database located at Hôpital Bicêtre near Paris,
and the Molecular Genetics Laboratory at the Edouard
Herriot University Hospital in Lyon. The PREDIR centre
strives to collect clinical and molecular data on all French
carriers of a mutation predisposing to renal cell tumours,
whereas the Lyon laboratory is the main provider of FLCN
germline analysis in France. We retrieved clinical data for
all patients with a diagnosis of molecularly-proven BHD,
and selected those with a history of renal cell tumour at
the time of genetic testing. All patients had signed an
informed consent form before genetic testing, as legally
required. Cases reported in two previous papers are
included in this study [10,11]. Follow-up data for included
patients are up-to-date as of 29 September 2014, the day
the final version of this manuscript was submitted.
Mutations were identified using both Sanger sequencing
of exons and their flanking regions and multiplex ligation
probe-dependent amplification (MLPA) on genomic DNA
extracted from blood. Detailed protocols are available on
request. Mutations were considered pathogenic if they
had been reported and reliably identified as such in the
FLCN mutation database (http://grenada.lumc.nl/LOVD2/
shared1), or for never-reported mutations, if they led to a
truncated protein.
Results
We ascertained a total of 124 BHD patients from 72
distinct families. Thirty-three had a history of renal cell
tumour (Tables 1 and 2). Twenty-one were male, 12
female. Median age at diagnosis of first tumour was 46
(age range 20–83). Twenty cases had one tumour, four had
two tumours, and nine had multifocal (three or more) tu-
mours. Most cases (23/33, 70%) had oncocytoma or RCC
of the chromophobe or hybrid chromophobe-oncocytoma
type, three had clear cell RCC (9%), one had papillary RCCwith interspersed eosinophilic cells, and one had undif-
ferentiated RCC. Histopathology was unavailable for
five patients, most often because their tumours were
radiologically characteristic but too small to justify sur-
gery. The most common histological types are illustrated
in Figure 1.
In addition to renal cell tumours, 29/33 cases also had
documented extra-renal BHD manifestations. Twenty-two
(67%) had lung cysts and/or pneumothoraces, and 19
(58%) had fibrofolliculomas (twelve cases had both
pulmonary and dermatological manifestations).
There were 21 distinct mutations: frameshift (n = 10),
missense (n = 4), nonsense (n = 4), splice site (n = 2) and
in frame deletion (n = 1).
Among those 33 patients, four had metastatic RCC,
either at the time of diagnosis or subsequently. All
presented with symptoms that led to the diagnosis of
RCC. Case 13851 had RCC age 35, he had undergone
successful nephrectomy at the time. A solitary lung
lesion was found incidentally age 58 on a CT scan that
was prescribed after an episode of malignant hypertension.
It was surgically removed and pathological examination
showed it was a metastasis from a poorly differentiated
RCC. The patient died of ischemic stroke four years after
surgical resection of the metastasis, and there was no
evidence of cancer relapse at the time. Case 19398 was
diagnosed age 42 with bilateral multifocal hybrid
chromophobe- oncocytoma RCC and liver metastases.
Biopsy of a left renal tumour led to the pathological
diagnosis. No further surgical procedure was carried
out. For the first three years, she was under systemic
therapy with sunitinib, everolimus and then temsirolimus,
and disease stability was achieved. All treatments were
then stopped. Eight years after the initial diagnosis, she is
clinically well and the liver metastases are radiologically
stable. Case 21310 had left nephrectomy age 46 for chro-
mophobe RCC, and subsequently presented with liver and
lung metastases. She is still alive five years after the metas-
tases were first observed, even though slow radiological
and clinical progression has justified treatment with suni-
tinib, axitinib, everolimus, bevacizumab and pazopanib.
Finally, case 22973 had right nephrectomy age 56 for a
chromophobe RCC. He received adjuvant radiotherapy for
multiple, metastatic retroperitoneal lymph-nodes that
could not be removed surgically. Seven years later, there
are no radiological or clinical signs of disease progression.
Discussion
Our series of 33 cases is one of the largest ever published
[4-8]. This study confirms that cases can have either
unifocal disease, or multiple tumours, and that most
renal cell tumours are oncocytomas or RCC of chromo-
phobe or hybrid chromophobe-oncocytoma histology
[4-6]. Other histologies are however associated with the
Table 1 Birt-Hogg-Dubé patients with renal tumours










11525 M c.1285dup, p.His429Profs*27 73 Multifocal Ch, H FF 30 05/2014
11528 M c.1285dup, p.His429Profs*27 83 2 N/A FF, PNO 103 11/2013
11545 M c.1285dup, p.His429Profs*27 39 1 N/A Lung cysts 65 05/2011
13851 M c.1285dup, p.His429Profs*27 35 1 (Mt) Und FF 225 03/2003 (D)
14381 M c.755dup, p.Cys253Valfs*39 62 1 CC FF 150 05/2009
14840 M c.1285dup, p.His429Profs*27 20 1 N/A FF, PNO 672 02/2011
15842 F c.828del, p.Ala277Leufs*16 38 1 Ch - 176 02/2014
19276 M c.1062 + 2 T > G 56 2 Ch, H FF 96 05/2011
19398 F c.663dup, p.Met222Aspfs*26 42 Multifocal (Mt) H PNO 115 09/2014
20471 F c.1285dup, p.His429Profs*27 34 Multifocal Ch, O FF, PNO 248 01/2014
20472 M c.67G > T, p.Glu23* 43 1 Ch PNO 132 03/2014
21310 F c.1198G > A, p.Val400Ile 46 1(Mt) Ch - 99 07/2014
22973 M c.1523A > G, p.Lys508Arg 56 1 (Mt) Ch FF, PNO 96 03/2014
25891 F c.318C > G, p.Tyr106* 25 1 P Lung cysts 96 03/2014
26016 M c.1300G > A, p.Glu434Lys 48 Multifocal Ch, H FF 16 05/2011
27674 M c.616A > T, p.Lys206* 56 1 Ch PNO 93 05/2013
28190 M c.1367_1398del, p.Asp456Glyfs*19 53 1 O Lung cysts 16 09/2012
28535 F c.1063-2A > G 51 1 Ch FF, lung cysts 72 04/2014
28537 F c.1300G > A, p.Glu434Lys 47 2 H PNO 20 02/2014
28590 M c.1285dup, p.His429Profs*27 47 1 Ch FF, lung cysts 13 05/2013
31122 F c.1285dup, p.His429Profs*27 41 Multifocal CC Lung cysts, PNO 264 06/2005
36616 M c.1285del, p.His429Thrfs*39 40 1 N/A FF 312 01/2008
37644 M c.958dup, p.Arg320Profs*70 41 2 O FF, PNO 6 07/2008
37673 M c.610_611delinsTA, p.Ala204* 44 Multifocal Ch - 9 07/2008
40154 F c.1528_1530del, p.Glu510del 30 Multifocal O - N/A 02/2009
40893 M c.323G > T, p.Ser108Ile 51 1 CC FF, PNO 45 03/2013
42207 F c.1300G > A, p.Glu434Lys 54 1 Ch FF, PNO 74 01/2014
42337 M c.1300G > A, p.Glu434Lys 50 1 H FF, lung cysts, PNO 60 02/2014
47950 M c.1458del, p.Ile486Metfs*5 44 Multifocal O FF 24 02/2014
47639 F c.57_58del, p.Phe20Leufs*16 44 1 H PNO 43 05/2014
48746 M c.1318del, p.Glu440Argfs*28 54 1 Ch FF, lung cysts 35 01/2014
48781 F c.1285dup, p.His429Profs*27 55 1 N/A FF, PNO 80 02/2013
50335 M c.958dup, p.Arg320Profs*70 39 Multifocal O PNO 24 06/2014
All patients were alive at last follow-up, unless specified otherwise. CC, clear cell renal cell carcinoma. Ch, chromophobe renal cell carcinoma. D, deceased. FF,
fibrofolliculomas, F-U, follow-up. H, hybrid chromophobe- oncocytoma renal cell carcinoma. Mt, metastatic disease. N/A, not available. O, oncocytoma. P, papillary
renal cell carcinoma, type undetermined. PNO, pneumothorax. Und, undifferentiated.
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cases, 3 (9%) had clear cell carcinomas. Given that they
are not typical in BHD, all clear cell RCC were reviewed
by one of our expert pathologists, and confirmation was
obtained. This proportion is similar to what has been
reported in the past, and clinicians should therefore
remain alert to the possibility of BHD in patients with
clear cell RCC, especially if there are associated mani-
festations [6].The age at renal cell tumour diagnosis varied between
20 and 83, with a median age of 46. Of special interest
was the fact that two patients presented with a renal cell
tumour in their twenties, highlighting the need for regu-
lar surveillance from an early age [12]. This surveillance
should be continued with no upper age limit and as long
as the patients are in good condition, as one patient with
two tumours in his eighties was successfully treated by
percutaneous radiofrequency ablation.
Table 2 Summary of clinical and histopathological





















§twelve patients had both pulmonary and dermatological manifestations. RCC,
renal call carcinoma.
Figure 1 Main types of renal tumours seen in our patients with BHD
chromophobe-oncytoma carcinoma (C), and clear cell carcinoma (D).
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all ascertained BHD patients (33/124), and 34% of those
for which we have evidence of renal imaging (33/98). This
observation is remarkably consistent with two large stud-
ies from the United States National Cancer Institute that
reported overall tumour frequencies of 29% and 34% in
BHD patients evaluated by CT scan [4,5]. We expect the
proportion in our study to be representative of the true
renal cell tumour risk associated with the syndrome, as
French index cases are offered FLCN genetic analysis
because they present with all types of clinical manifesta-
tions suggestive of BHD.
An exhaustive description of extrarenal manifestations
is beyond the scope of this paper. Nevertheless, 67% and
58% of our cases also had pulmonary and dermatological
manifestations respectively, in addition to RCC. These
figures represent the minimal prevalence as pulmonary
assessment by CT scan and examination by a dermatologist
knowledgeable in the syndrome was not systematic.
In our series, four patients had metastatic, albeit indo-
lent RCC. Comprehensive family data was collected for
all patients in this series, and we have no knowledge of
other relatives (deceased or alive) with metastatic RCC
who were not tested for FLCN mutations, and who were
therefore not included in this study. Very few cases of
metastatic RCC associated with BHD have been de-
scribed. Pavlovich et al. and Houweling et al. reported
respectively two and five such cases; all died rapidly. Oncocytoma (A), chromophobe carcinoma (B), hybrid
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gery, radiotherapy, immunotherapy and chemotherapy,
and the good prognosis associated with metastatic disease
in our study contrasts with these earlier reports [8,13].
Three of the four patients reported here are still alive
more than five years after the metastases were diagnosed,
while the fourth died of unrelated causes four years after
a lung metastasis had been removed. Whether these
observations reflect a specific behaviour only seen in
BHD requires further investigation. Another hypothesis
is that metastatic RCC in BHD patients is more sensitive
to tyrosine kinase and mTOR inhibitors such as suniti-
nib and everolimus (two recently-developed drugs that
are now routinely used in the treatment of metastatic
RCC), as suggested for example by the mTOR signalling
pathway activation seen in kidney tumours associated
with the syndrome, but that would not account for the
good prognosis of cases 13851 and 22973 who received
no systemic treatment [14]. As shown in Table 1, most
patients in our study are followed up medically, with
relevant information being collected by the team in
charge on a regular basis. There is however a minority
from which we have not heard in the last few years, and
we cannot rule out with certainty the possibility of
aggressive metastatic disease in these patients.
Conclusions
The eponym syndrome was first described over 35 years
ago by Birt, Hogg and Dubé [15]. However, the FLCN
gene was only identified in 2002 [16]. The recent mo-
lecular characterisation of the syndrome, added to the
fact that like most genetic diseases BHD is rare in the
general population, means there are only limited data on
the topic in the literature. As a result, this large and
multicentric study will improve knowledge of the syn-
drome among geneticists, urologists and oncologists in-
volved in the assessment and management of patients
with a suspected or established genetic predisposition to
renal cell tumours. It is of utmost importance to identify
individuals with a high probability of developing renal
cell tumours, so that they, and their at-risk relatives can
benefit from personalised surveillance and management.
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